Drugs / SG301 Injection
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06508983 | Jun 2024 → Mar 2027 expected | refractory plasma cell neoplasm | Hangzhou Sumgen Biotech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SG301 Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06508983 ↗ |
| Route | Intravenous | “Route of administration: intravenous” NCT06508983 ↗ |